Bifogade filer
Kurs
+12,37%
Likviditet
0,47 MSEK
Kalender
Tid* | ||
2025-03-13 | 13:30 | Kvartalsrapport 2025-Q3 |
2025-01-08 | - | Extra Bolagsstämma 2025 |
2024-11-28 | - | Kvartalsrapport 2025-Q2 |
2024-10-12 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2024-09-16 | - | Kvartalsrapport 2025-Q1 |
2024-06-26 | - | Bokslutskommuniké 2024 |
2024-03-27 | - | Kvartalsrapport 2024-Q3 |
2023-12-21 | - | Kvartalsrapport 2024-Q2 |
2023-11-15 | - | Extra Bolagsstämma 2024 |
2023-10-27 | - | Årsstämma |
2023-10-13 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2023-09-20 | - | Kvartalsrapport 2024-Q1 |
2023-06-23 | - | Bokslutskommuniké 2023 |
2023-05-09 | - | Extra Bolagsstämma 2023 |
2023-03-28 | - | Kvartalsrapport 2023-Q3 |
2022-12-21 | - | Kvartalsrapport 2023-Q2 |
2022-10-31 | - | Årsstämma |
2022-10-14 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2022-09-29 | - | Kvartalsrapport 2023-Q1 |
2022-06-29 | - | Bokslutskommuniké 2022 |
2022-03-21 | - | Kvartalsrapport 2022-Q3 |
2022-03-15 | - | Extra Bolagsstämma 2022 |
2021-12-29 | - | Kvartalsrapport 2022-Q2 |
2021-10-20 | - | Extra Bolagsstämma 2021 |
2021-10-11 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2021-09-29 | - | Kvartalsrapport 2022-Q1 |
2021-06-24 | - | Bokslutskommuniké 2021 |
2021-03-16 | - | Kvartalsrapport 2021-Q3 |
2020-12-14 | - | Kvartalsrapport 2021-Q2 |
2020-10-20 | - | Årsstämma |
2020-10-15 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2020-09-28 | - | Kvartalsrapport 2021-Q1 |
2020-06-25 | - | Bokslutskommuniké 2020 |
2020-03-12 | - | Kvartalsrapport 2020-Q3 |
2019-12-17 | - | Kvartalsrapport 2020-Q2 |
2019-10-16 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2019-10-15 | - | Årsstämma |
2018-09-27 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2018-09-26 | - | Årsstämma |
2018-06-18 | - | Extra Bolagsstämma 2019 |
2018-06-12 | - | Bokslutskommuniké 2018 |
2018-03-12 | - | Kvartalsrapport 2018-Q3 |
2017-09-26 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2017-09-25 | - | Årsstämma |
2017-09-11 | - | Kvartalsrapport 2018-Q1 |
2017-06-19 | - | Bokslutskommuniké 2017 |
2017-03-13 | - | Kvartalsrapport 2017-Q3 |
2017-01-01 | - | Extra Bolagsstämma 2018 |
2016-11-30 | - | Kvartalsrapport 2017-Q2 |
2016-09-06 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2016-09-05 | - | Årsstämma |
2016-09-05 | - | Kvartalsrapport 2017-Q1 |
2016-06-13 | - | Bokslutskommuniké 2016 |
2016-02-22 | - | Kvartalsrapport 2016-Q3 |
2016-02-16 | - | Extra Bolagsstämma 2017 |
2015-11-30 | - | Kvartalsrapport 2016-Q2 |
2015-09-08 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2015-09-07 | - | Årsstämma |
2015-09-07 | - | Kvartalsrapport 2016-Q1 |
2015-06-16 | - | Bokslutskommuniké 2015 |
2015-03-16 | - | Kvartalsrapport 2015-Q3 |
2014-12-01 | - | Kvartalsrapport 2015-Q2 |
2014-10-07 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
2014-10-06 | - | Årsstämma |
2014-10-06 | - | Kvartalsrapport 2015-Q1 |
2014-06-30 | - | Bokslutskommuniké 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
Thursday, 27 April 2023, is the last day of trading in warrants of series TO 3, which were issued in connection with Phase Holographic Imaging PHI AB's ("PHI" or the "Company") rights issue of units that was announced on 22 February 2022. The exercise period runs until and including 2 May 2023.
Each warrant of series TO 3 entitles the holder to subscribe for one (1) new share in PHI at a price of SEK 3.78 per share during the exercise period that started on 11 April 2023 and runs until and including 2 May 2023.
For warrants not to expire worthless, warrant holders must subscribe for new shares, with the support of warrants, at 17:00 CEST on 2 May 2023, at the latest, alternatively sell warrants no later than on 27 April 2023.
For more information, including a more detailed description of PHI's operations as well as complete terms and conditions, please refer to the prospectus that was prepared in connection with the rights issue and published by the Company on 28 March 2023. The prospectus is available on PHI's website (https://phiab.com/ir/). More information about the Company and the offer is also available on the websites of PHI (www.phiab.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se). Complete terms and conditions for warrants of series TO 3 are available on the Company's website (www.phiab.com).
Important dates27 April 2023: Last day of trading in warrants
2 May 2023: The exercise period ends
4 May 2023: Planned communication of the outcome of the warrant exercise
23 May 2023: Planned conversion of interim shares to ordinary shares
Advisors
In connection with the exercise of warrants of series TO 3, Sedermera Corporate Finance AB is acting as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent. Shark Communication AB is assisting the Company with advice regarding communication.
For more information about the warrants of series TO 3, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se (info@sedermera.se)
www.sedermera.se
Patrik Eschricht
E-mail: ir@phiab.com (ir@phiab.se)
www.phiab.com - Live cell imaging & analysis